Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Protagonist Therapeutics (PTGX) Revenue (2017 - 2025)

Protagonist Therapeutics' Revenue history spans 9 years, with the latest figure at $7.4 million for Q4 2025.

  • For Q4 2025, Revenue fell 95.49% year-over-year to $7.4 million; the TTM value through Dec 2025 reached $46.0 million, down 89.27%, while the annual FY2025 figure was $46.0 million, 89.41% down from the prior year.
  • Revenue for Q4 2025 was $7.4 million at Protagonist Therapeutics, up from $4.7 million in the prior quarter.
  • Across five years, Revenue topped out at $255.0 million in Q1 2024 and bottomed at $859000.0 in Q2 2022.
  • The 5-year median for Revenue is $8.0 million (2021), against an average of $40.7 million.
  • The largest annual shift saw Revenue soared 6885.04% in 2021 before it tumbled 95.49% in 2025.
  • A 5-year view of Revenue shows it stood at $8.6 million in 2021, then soared by 1205.56% to $112.5 million in 2022, then plummeted by 91.11% to $10.0 million in 2023, then skyrocketed by 1550.0% to $165.0 million in 2024, then crashed by 95.49% to $7.4 million in 2025.
  • Per Business Quant, the three most recent readings for PTGX's Revenue are $7.4 million (Q4 2025), $4.7 million (Q3 2025), and $5.5 million (Q2 2025).